Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Jos A Stigt"'
Autor:
Vincent D. de Jager, Jos A. Stigt, Maarten Niemantsverdriet, Arja ter Elst, Anthonie J. van der Wekken
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-4 (2024)
Abstract Precision cancer medicine has changed the treatment paradigm of patients with non-small cell lung cancer (NSCLC) with specific molecular aberrations. A major challenge is management of the resistance that tumor cells eventually develop again
Externí odkaz:
https://doaj.org/article/66cbe8d1f3b64337b77a6fb34250db83
Autor:
Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
Publikováno v:
ERJ Open Research, Vol 8, Iss 4 (2022)
Introduction Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy. In this randomised controlled trial we investigated whether i
Externí odkaz:
https://doaj.org/article/7a4d1f9500d043fca5a9dd6a08afeeba
Autor:
Floris Dammeijer, Cornedine J. De Gooijer, Mandy van Gulijk, Melanie Lukkes, Larissa Klaase, Lysanne A. Lievense, Cynthia Waasdorp, Merel Jebbink, Gerben P. Bootsma, Jos A. Stigt, Bonne Biesma, Margaretha E.H. Kaijen-Lambers, Joanne Mankor, Heleen Vroman, Robin Cornelissen, Paul Baas, Vincent Van der Noort, Jacobus A. Burgers, Joachim G. Aerts
Publikováno v:
EBioMedicine, Vol 64, Iss , Pp 103160- (2021)
Background: Gemcitabine is a frequently used chemotherapeutic agent but its effects on the immune system are incompletely understood. Recently, the randomized NVALT19-trial revealed that maintenance gemcitabine after first-line chemotherapy significa
Externí odkaz:
https://doaj.org/article/3c5ff16d06e342ff8c1730cb7bdef69d
Publikováno v:
J Thorac Dis
Background Robot assisted thoracic surgery (RATS) is the minimally invasive surgical technique of choice for treatment of patients with non-small cell lung cancer (NSCLC), at the Isala Hospital. The aim of this study is to compare clinical and pathol
Autor:
Birgitta I. Hiddinga, Arja ter Elst, T. Jeroen N. Hiltermann, Matthew Groves, Bart Koopman, Harry J.M. Groen, Anthonie J. van der Wekken, Ed Schuuring, Lucie Hijmering-Kappelle, Wim Timens, Anke van den Berg, Juliana F Vilacha, Léon C van Kempen, Jos A. Stigt
Publikováno v:
JCO Precision Oncology, 4, 393-410. AMER SOC CLINICAL ONCOLOGY
PURPOSE Molecular tumor boards (MTBs) provide physicians with a treatment recommendation for complex tumor-specific genomic alterations. National and international consensus to reach a recommendation is lacking. In this article, we analyze the effect
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
Autor:
A-M.C. Dingemans, Jules L. Derks, B.C.M. Hermans, Jos A. Stigt, E C van den Broek, Lisa M. Hillen, Harry J.M. Groen, R.J. van Suylen, Ernst-Jan M. Speel
Publikováno v:
Endocrine Connections
Endocrine Connections, 8(12), 1600-1606. BioScientifica Ltd.
Endocrine Connections, 8(12), 1600-1606. BIOSCIENTIFICA LTD
Endocrine Connections, Vol 8, Iss 12, Pp 1600-1606 (2019)
Endocrine Connections, 8(12), 1600-1606. BioScientifica Ltd.
Endocrine Connections, 8(12), 1600-1606. BIOSCIENTIFICA LTD
Endocrine Connections, Vol 8, Iss 12, Pp 1600-1606 (2019)
Introduction Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring
Autor:
A. J. van der Wekken, Vincent van der Noort, M. Goosens, J.D.J. Janssen, J.A. Staal Van Den Brekel, Frans H. Krouwels, E Schuuring, Joachim G.J.V. Aerts, B. E. van den Borne, P.M. Van De Berg, W. H. van Geffen, A.J. de Langen, Wim Timens, E.F. Smit, Rolof G.P. Gijtenbeek, H.J.M. Groen, T.J.N. Hilterman, F.A. Wilschut, Jos A. Stigt
Publikováno v:
European Respiratory Journal, 58. EUROPEAN RESPIRATORY SOC JOURNALS LTD
Publikováno v:
J Thorac Dis
BACKGROUND: Outpatient or ambulatory treatment for prolonged air leak (PAL) has been reported previously in various studies. Evidence regarding efficiency and safety is nevertheless poor. This report describes the experience of 10 years ambulatory ca
Autor:
Eline G. M. Steenhuis, Ivonne J. H. Schoenaker, Jan Willem B. De Groot, Jos A. Stigt, Onne Reerink, Wouter H. De Vos tot Nederveen Cappel, Henderik L. Van Westreenen, Richard M. Brohet
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 13; Pages: 3828
Purpose: Worldwide, colorectal carcinoma (CRC) has a high incidence and a substantial cancer-related mortality. The recurrence risk is 30–50% and lung metastases are common. Treatment of lung metastases with stereotactic ablative radiotherapy (SABR
Autor:
T. Jeroen N. Hiltermann, Jiacong Wei, Arja ter Elst, Pei Meng, Anthonie J. van der Wekken, Lennart Johansson, Mohamed Z. Alimohamed, Harry J.M. Groen, M. M. Terpstra, Anke van Rijk, Menno Tamminga, Klaas Kok, Rolof P G Gijtenbeek, Anke van den Berg, John W. G. van Putten, Jos A. Stigt, Frank J. G. Scherpen
Publikováno v:
Targeted Oncology
Targeted oncology. SPRINGER
Targeted oncology. SPRINGER
Background The clinical relevance of epidermal growth factor receptor (EGFR) copy number gain in patients with EGFR mutated advanced non-small cell lung cancer on first-line tyrosine kinase inhibitor treatment has not been fully elucidated. Objective